bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
December 15 2022 - 8:30AM
Business Wire
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a
biotechnology company addressing the need for noninvasive diagnosis
of early-stage cancer and diseases of the lung, as well as targeted
cancer treatment, today announced that they have made a key
promotion and additions to their staff.
Jennifer Rebeles, Ph.D., has been promoted to Vice President of
Diagnostics. Dr. Rebeles joined bioAffinity in 2019 as Director of
Diagnostics where she led the team of scientists in the research
and development of the company’s first product, CyPath® Lung, an
automated flow cytometry tests that has shown high sensitivity and
specificity for the detection of early-stage lung cancer. Dr.
Rebeles was a research scientist with the United States Air Force
59th Medical Wing for Science and Technology where she performed
recurring analyses on research portfolios to identify critical gaps
in military medicine and proposed new projects to address those
needs. Prior to that, she served as the Flow Cytometry and
Microarray Technical Director at the Greehey Children’s Cancer
Research Institute of the University of Texas Health Science Center
at San Antonio, TX. Dr. Rebeles received her Ph.D. in Nutritional
Biochemistry from the University of North Carolina Chapel Hill
Gillings School of Global Public Health with training in
nutritional immunology by investigating the effects of obesity on
the immune response to influenza infection.
“Dr. Rebeles has shown exceptional leadership and scientific
acumen in development and commercialization of CyPath® Lung,” said
bioAffinity Executive Vice President and Chief Medical and Science
Officer Vivienne Rebel, MD, Ph.D. “She is an expert in flow
cytometry, a technology that is the foundation of our diagnostic
platform. Her promotion to Vice President is well earned, given the
precision and exacting approach to research and management.”
In addition, Rossella Titone, Ph.D., and Alvaro Souto Padron de
Figueiredo, Ph.D., have joined bioAffinity as research scientists
in the company’s Diagnostics Division.
Dr. Titone joins bioAffinity from the Texas Biomedical Research
Institute where, as a Postdoctoral Scientist, she conducted
biomedical research in the study of molecular mechanisms of viral
dissemination and also spent several years as a researcher at the
University of Texas Southwestern Medical Center. She participated
in the Postdoctoral Program in Advance Research, Corneal Biology at
the University of Texas Southwestern and earned her Ph.D. in
Biotechnologies for Human Health, Biomedical Biotechnology and
Cancer Research from the University of Eastern Piedmont.
Additionally, she earned her Master’s Degree in Biomedical
Biotechnologies, Cancer Biology from the University of Siena and a
Bachelor’s Degree in Biomedical Biotechnology, Molecular Cancer
Biology from the University of Palermo.
Dr. Souto Padron de Figueiredo joins bioAffinity from the
Division of Hematology & Oncology at the University of Texas
Health Science Center at San Antonio-South Texas Research Facility,
Adult Cancer Program, where he worked on a National Institute of
Health-funded research grant investigating effects of different
immune co-signaling therapy in the treatment of various
pre-clinical cancer models and testing new drugs for pharmaceutical
companies. He earned his Ph.D. and Master’s Degree in Biological
Sciences (Physiology) from the Federal University of Rio de Janeiro
UFRJ, and his Bachelor’s in Nutrition from the Federal University
of State of Rio de Janeiro, UNIRIO.
“bioAffinity Technologies is grounded in strong scientific
research and skilled, experienced scientists,” said bioAffinity
President and CEO Maria Zannes. “These men and women are
innovative, dedicated and committed to commercialization of CyPath®
Lung and development of additional diagnostics for lung diseases
and tests for cancer.”
About bioAffinity Technologies,
Inc.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses
the need for noninvasive diagnosis of early-stage cancer and
diseases of the lung, and targeted cancer treatment. The Company’s
first product, CyPath® Lung, is a non-invasive test that has shown
high sensitivity and specificity for the detection of early-stage
lung cancer. Precision Pathology Services licensed and developed
CyPath® Lung as a Laboratory Developed Test (LDT) and has begun
test marketing in Texas. OncoSelect® Therapeutics, LLC, a
subsidiary of bioAffinity Technologies, is advancing its
discoveries shown in vitro to kill cancer cells without harm to
normal cells. Research and optimization of the Company’s platform
technologies are conducted in its laboratories at The University of
Texas at San Antonio.
Forward-Looking
Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221215005348/en/
Company Contact: Maria Zannes, President & Chief
Executive Officer mz@bioaffinitytech.com
Investor Relations Contact: Tiberend Strategic Advisors,
Inc. Jonathan Nugent jnugent@tiberend.com or David Irish
dirish@tiberend.com
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Mar 2024 to Apr 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Apr 2023 to Apr 2024